Nasdaq
$6.22▲ 0.57%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.22BShares out 3.600M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
21- 9.24After-hours26.09.25 05:194Ownership#●●●
PRECIGEN, INC.
Insider Thomasian Harry Jr. of Precigen, Inc. filed a Form 4 on September 24, 2026, reporting a change in beneficial ownership of securities effective September 23, 2026. This filing serves as an official record of the insider's equity transaction.…more
$6.22+0.57%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.29Closed26.08.29 09:394Ownership
PRECIGEN, INC.
Director Jeffrey B. Kindler of Precigen, Inc. filed a Form 4 report on August 28, 2026, disclosing changes in beneficial ownership of securities as of August 26, 2026. This filing serves as an official record of the insider's equity position change.…more
$6.22+0.57%vs prev closeView filingShare - 8.26After-hours26.08.27 05:43144Ownership
PRECIGEN, INC.
Jeffrey B. Kindler, a director of Precigen, Inc., filed an SEC Form 144 on August 26, 2026, to report a proposed sale of company shares. This filing serves as a standard notification for the disposal of shares by an insider.…more
$6.22+0.57%vs prev closeView filingShare
20 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.21Pre-market26.09.21 20:09#●●●#●●●
Precigen Receives FDA Platform Technology Designation for AdenoVerse
Precigen announced that its AdenoVerse immunotherapy platform has been granted platform technology designation by the FDA. This designation is expected to potentially expedite the development and regulatory review process for its pipeline.…more
$6.22+0.57%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga